These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 12365480)

  • 1. Survival impact of tamoxifen use for breast cancer risk reduction: projections from a patient-specific Markov model.
    Col NF; Goldberg RJ; Orr RK; Erban JK; Fortin JM; Chlebowski RT
    Med Decis Making; 2002; 22(5):386-93. PubMed ID: 12365480
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention: drug pricing and mortality: the case of tamoxifen.
    Melnikow J; Kuenneth C; Helms LJ; Barnato A; Kuppermann M; Birch S; Nuovo J
    Cancer; 2006 Sep; 107(5):950-8. PubMed ID: 16865680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamoxifen's trials and tribulations.
    Marshall E
    Science; 1995 Nov; 270(5238):910. PubMed ID: 7481787
    [No Abstract]   [Full Text] [Related]  

  • 4. The decision to enter a randomized trial of tamoxifen for the prevention of breast cancer in healthy women: an analysis of the tradeoffs.
    Nease RF; Ross JM
    Am J Med; 1995 Aug; 99(2):180-9. PubMed ID: 7625423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The tamoxifen controversy.
    Crabbe WW
    Oncol Nurs Forum; 1996 Jun; 23(5):761-6. PubMed ID: 8792346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Survival impact of adjuvant tamoxifen on competing causes of mortality in breast cancer survivors, with analysis of mortality from contralateral breast cancer, cardiovascular events, endometrial cancer, and thromboembolic episodes.
    Ragaz J; Coldman A
    J Clin Oncol; 1998 Jun; 16(6):2018-24. PubMed ID: 9626198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.
    Chlebowski RT; Collyar DE; Somerfield MR; Pfister DG
    J Clin Oncol; 1999 Jun; 17(6):1939-55. PubMed ID: 10561236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of tamoxifen chemoprevention for breast cancer in very high-risk women: a cost-effectiveness analysis.
    Hershman D; Sundararajan V; Jacobson JS; Heitjan DF; Neugut AI; Grann VR
    J Clin Oncol; 2002 Jan; 20(1):9-16. PubMed ID: 11773148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First do no harm: extending the debate on the provision of preventive tamoxifen.
    Will BP; Nobrega KM; Berthelot JM; Flanagan W; Wolfson MC; Logan DM; Evans WK
    Br J Cancer; 2001 Nov; 85(9):1280-8. PubMed ID: 11720461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The benefits and costs of tamoxifen for breast cancer prevention.
    Eckermann SD; Martin AJ; Stockler MR; Simes RJ
    Aust N Z J Public Health; 2003; 27(1):34-40. PubMed ID: 14705265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The cost effectiveness of tamoxifen in the prevention of breast cancer.
    Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
    Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indices of differential endometrial: myometrial growth may be used to improve the reliability of detecting endometrial neoplasia in women on tamoxifen.
    Pepper JM; Oyesanya OA; Dewart PJ; Howell A; Seif MW
    Ultrasound Obstet Gynecol; 1996 Dec; 8(6):408-11. PubMed ID: 9014281
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tamoxifen's clinical applications: old and new.
    Buzdar AU
    Arch Fam Med; 2000; 9(9):906-12. PubMed ID: 11031399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.
    Grann VR; Jacobson JS; Whang W; Hershman D; Heitjan DF; Antman KH; Neugut AI
    Cancer J Sci Am; 2000; 6(1):13-20. PubMed ID: 10696733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study.
    Fisher B; Costantino JP; Wickerham DL; Cecchini RS; Cronin WM; Robidoux A; Bevers TB; Kavanah MT; Atkins JN; Margolese RG; Runowicz CD; James JM; Ford LG; Wolmark N
    J Natl Cancer Inst; 2005 Nov; 97(22):1652-62. PubMed ID: 16288118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamoxifen's effect in women with breast cancer.
    Bryson A; Massey J
    Lancet; 2001 Apr; 357(9264):1291; author reply 1291-2. PubMed ID: 11421213
    [No Abstract]   [Full Text] [Related]  

  • 17. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
    Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
    Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [-Tamoxifen and the endometrium: monitoring and evaluation of endometrial changes-].
    Rageth JC; Bronz L; Granberg S
    Arch Gynecol Obstet; 1995; 256 Suppl():S122-7. PubMed ID: 8619646
    [No Abstract]   [Full Text] [Related]  

  • 19. Tamoxifen, screening and new oestrogen receptor modulators.
    Neven P; Vergote I
    Best Pract Res Clin Obstet Gynaecol; 2001 Jun; 15(3):365-80. PubMed ID: 11476559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of endometrial proliferation in pipelle biopsies in tamoxifen-treated postmenopausal women with breast cancer in Kuwait.
    Al-Azemi M; Labib NS; Motawy MM; Temmim L; Moussa MA; Omu AE
    Med Princ Pract; 2004; 13(1):30-4. PubMed ID: 14657616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.